A5079098188- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Pain Management and Opioid Use
- Cancer-related cognitive impairment studies
- Pain Mechanisms and Treatments
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Cancer survivorship and care
- Pharmacological Effects and Toxicity Studies
- Glioma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Cardiac Health and Mental Health
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Hematopoietic Stem Cell Transplantation
- Neonatal Health and Biochemistry
- Pancreatic function and diabetes
- Heme Oxygenase-1 and Carbon Monoxide
Istituti di Ricovero e Cura a Carattere Scientifico
2025
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2023-2025
Azienda Ospedaliera Universitaria Integrata Verona
2016
Ospedale Papa Giovanni XXIII
2013-2016
Azienda Ospedaliero Universitaria Ospedali Riuniti
2010-2013
University of Milano-Bicocca
2007
Highlights•Minimal residual disease positivity in acute lymphoblastic leukemia is a major risk factor for relapse and poor outcomes•We evaluated the impact of minimal levels before allogeneic hematopoietic stem cell transplantation on outcomes patients with Philadelphia chromosome–positive leukemia•Patients measurable have higher relapse•Achieving negativity should be prerequisite successful transplantationAbstractAllogeneic (alloHSCT) first complete remission (CR1) remains consolidation...
Carbon monoxide (CO) exposure of an islet donor frequently leads to allograft long-term survival and tolerance in recipients. We show here that CO confers its protective effects at least part by suppressing Toll-like receptor 4 (TLR4) up-regulation pancreatic beta cells. TLR4 is normally up-regulated islets during the isolation procedure; treatment with suppresses expression isolated as well transplanted grafts. allows initiation inflammation, which rejection; grafts from TLR4-deficient mice...
We evaluate the long-term results of a prospective clinical study enrolling more than 100 adult patients with Burkitt lymphoma/leukemia. Depending on extent disease, treatment consisted six to eight rituximab infusions and four courses intensive chemotherapy (attenuated in aged >55 years) high-dose methotrexate, fractionated ifosfamide/cyclophosphamide, other drugs rotation, intrathecal chemoprophylaxis. One-hundred five were treated (median age 47 years, range 17–78 years); 48% had...
Not available.
Developing optimal radiation-free central nervous system prophylaxis is a desirable goal in acute lymphoblastic leukemia, to avoid the long-term toxicity associated with cranial irradiation. In randomized, phase II trial enrolling 145 adult patients, we compared intrathecal liposomal cytarabine (50 mg: 6/8 injections B-/T-cell subsets, respectively) triple therapy (methotrexate/cytarabine/prednisone: 12 injections). Systemic included methotrexate plus or L-asparaginase courses, augmented 2.5...
Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission long-term survival in an adult patient
According to Europe's Beating Cancer Plan, the number of cancer survivors is growing every year and now estimated at over 12 million in Europe. A main objective European Commission ensure that can enjoy a high quality life, underlining role digital technology eHealth apps tools achieve this.The this study development user-centered artificial intelligence system facilitate input integration patient-related biopsychosocial data improve posttreatment well-being, health outcomes examine...
SUMMARY While adult acute lymphoblastic leukemia (ALL) is curable in 40–50% of the patients, individual prognosis rather unpredictable due to associated biological and clinical risk factors. In both B- T-precursor ALL, minimal residual disease (MRD) represents most sensitive prognostic marker, useful support critical treatment decisions, ranging from allogeneic stem cell transplantation patients with inadequate MRD response chemotherapy only responsive ones. This optimized risk-adapted...
<sec> <title>BACKGROUND</title> According to Europe’s Beating Cancer Plan, the number of cancer survivors is growing every year and now estimated at over 12 million in Europe. A main objective European Commission ensure that can enjoy a high quality life, underlining role digital technology eHealth apps tools achieve this. </sec> <title>OBJECTIVE</title> The this study development user-centered artificial intelligence system facilitate input integration patient-related biopsychosocial data...